|Bid||47.20 x 120700|
|Ask||47.22 x 6100|
|Day's Range||46.97 - 47.74|
|52 Week Range||38.28 - 71.00|
|Beta (3Y Monthly)||0.47|
|PE Ratio (TTM)||12.91|
|Earnings Date||Jul 30, 2019|
|Forward Dividend & Yield||0.80 (1.68%)|
|1y Target Est||N/A|
Stephan Sturm, CEO of German health care firm Fresenius, breaks down the sales growth the company saw in the first quarter of 2019.
I've been keeping an eye on Fresenius SE & Co. KGaA (FRA:FRE) because I'm attracted to its fundamentals. Looking at...
Fresenius SE & Co. KGaA (FRA:FRE) is a stock with outstanding fundamental characteristics. When we build an investment...
When a Californian company founded by a U.S. veteran wounded in Afghanistan sought to register a new medical device this year, it turned to Europe before the United States. "Now it has flipped," said Bill Colone, CEO of San Clemente-based Spinal Singularity, which hopes to launch a 'smart' catheter for men with spinal injuries or disease early next year after squeezing in its application under the old European rules. Colone is part of a chorus of industry voices warning that a switch to stricter European rules governing medical devices, due to come into force a year from now, will slow or even halt the release of products in Europe that could transform patients' lives.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Fresenius SE & Co. KGaA and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
Is Fresenius SE & Co. KGaA (FRA:FRE) a good dividend stock? How would you know? Dividend paying companies with growing...
Fresenius has approached potential suitors about the sale of its blood transfusion business, two people with knowledge of the matter said on Friday. Fresenius has hired Goldman Sachs to explore the sale, the people said.
Q1 2019 Update: Distributor Sales Take a Breather But Expected to Rebound. CytoSorbents (CTSO) reported financial results for their first quarter ending March 31st and provided a business update. While grant revenue was inline with expectations, product sales were a relative dud.
Fresenius reported a rise in first-quarter sales and operating profit on Thursday, helped by growth at its generic infusion drugs and dialysis units, as its troubled German hospital business showed signs of stabilisation. Currency-adjusted quarterly sales rose 5 percent to 8.5 billion euros (£7.3 billion), helped by growth at its Kabi infusion unit and separately listed Fresenius Medical Care. "All four Fresenius business segments have developed in line with our expectations, putting us well on course to meet our targets for the year," Chief Executive Stephan Sturm said.
On a per-share basis, the Bad Homburg, Germany-based company said it had net income of 50 cents. Earnings, adjusted for non-recurring costs, came to 59 cents per share. The dialysis services provider posted ...
Looking at Fresenius SE & Co. KGaA's (FRA:FRE) earnings update in December 2018, analyst forecasts seem fairly subdued, with earnings expected to grow by -7.2% in the upcoming y...
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Every investor in Fresenius SE & Co. KGaA (FRA:FRE) should be aware of the most powerful shareholder groups. Insiders of...
Generic drugmaker Akorn Inc said on Thursday the U.S. Food and Drug Administration had raised concerns about its manufacturing plant in Amityville, New York, that included a lack of records on the maintenance and cleaning of equipment. The FDA's issuance of the notice following an inspection of the plant, through a so-called Form 483, is the latest in a series of setbacks for Akorn and comes a month after the agency issued a warning letter related to another plant. The agency, following an inspection of the plant, also observed deficiencies in the facility's systems for keeping its equipment free from contamination, the FDA said in the form https://www.sec.gov/Archives/edgar/data/3116/000117184319001306/exh_992.htm dated Feb. 13.
Trade talks between the world's two biggest economies helped European shares rise on Wednesday, while the threat of a blocked merger sank shares in British supermarket Sainsbury's and a money laundering scandal hit Swedbank. Germany's trade-sensitive DAX led the way with a 0.8 percent gain and the pan-European STOXX 600 rose 0.7 percent after U.S. President Donald Trump said on Tuesday that trade talks with China were going well.
Fresenius expects earnings to grow faster than sales from 2020 after investments to improve its German hospitals and scale up its home dialysis business eat up profit this year, the German healthcare group said on Wednesday. Investors, who were disappointed last year after the company trimmed its guidance in October and abandoned in 2020 targets in December, were heartened by the outlook and the prospect of a 7 percent increase in the dividend to 0.80 euros per share. "2019 will be a year of investment in growth areas such as home dialysis, biosimilars and new hospital services and therapies," Chief Executive Stefan Sturm said in a statement.
The U.S. Federal Trade Commission has given Germany's Fresenius Medical Care AG and U.S. home dialysis equipment maker NxStage Medical Inc antitrust approval for their merger, the agency said on Tuesday. To win approval for the $2 billion deal, the companies agreed to sell NxStage's bloodline tubing set business, the agency said. Fresenius and NxStage together dominate the market for the single-use plastic tubes used during dialysis, the agency said.
Want to help shape the future of investing tools? Participate in a short research study and receive a 6-month subscription to the award winning Simply Wall St research tool (valued Read More...